60 related articles for article (PubMed ID: 1466965)
1. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
Buchbinder A; Zolla-Pazner S; Karwowska S; Gorny MK; Burda ST
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1395. PubMed ID: 1466965
[No Abstract] [Full Text] [Related]
2. Synergy between human monoclonal antibodies to HIV extends their effective biologic activity against homologous and divergent strains.
Buchbinder A; Karwowska S; Gorny MK; Burda ST; Zolla-Pazner S
AIDS Res Hum Retroviruses; 1992 Apr; 8(4):425-7. PubMed ID: 1599752
[No Abstract] [Full Text] [Related]
3. Epitopes of HIV-1 glycoproteins recognized by the human immune system.
Laal S; Zolla-Pazner S
Chem Immunol; 1993; 56():91-111. PubMed ID: 7680869
[No Abstract] [Full Text] [Related]
4. Discontinuous epitopes on gp120 important in HIV-1 neutralization.
Ho DD; Fung MS; Yoshiyama H; Cao Y; Robinson JE
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1337-9. PubMed ID: 1281654
[No Abstract] [Full Text] [Related]
5. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.
Zolla-Pazner S; Zhong P; Revesz K; Volsky B; Williams C; Nyambi P; Gorny MK
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1254-8. PubMed ID: 15588347
[TBL] [Abstract][Full Text] [Related]
6. Type-specific and cross-reactive neutralizing antisera against HIV elicited by V3-peptide heptalysine octomers.
Looney DJ; Li M; Walfield A; Hosein B; Badel P; Wang CY; Wong-Staal F
AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1381. PubMed ID: 1466961
[No Abstract] [Full Text] [Related]
7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
9. Complementary and synergistic activities of anti-V3, CD4bs and CD4i antibodies derived from a single individual can cover a wide range of HIV-1 strains.
Ramirez Valdez KP; Kuwata T; Maruta Y; Tanaka K; Alam M; Yoshimura K; Matsushita S
Virology; 2015 Jan; 475():187-203. PubMed ID: 25486586
[TBL] [Abstract][Full Text] [Related]
10. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
11. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
[No Abstract] [Full Text] [Related]
12. Antisera raised against the second variable region of the external envelope glycoprotein of human immunodeficiency virus type 1 cross-neutralize and show an increased neutralization index when they act together with antisera to the V3 neutralization epitope.
Davis D; Stephens DM; Carne CA; Lachmann PJ
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2609-17. PubMed ID: 7506300
[TBL] [Abstract][Full Text] [Related]
13. Human antibodies to HIV-1 by recombinant DNA methods.
Burton DR; Barbas CF
Chem Immunol; 1993; 56():112-26. PubMed ID: 8452652
[No Abstract] [Full Text] [Related]
14. Neutralizing antibodies decrease the envelope fluidity of HIV-1.
Harada S; Monde K; Tanaka Y; Kimura T; Maeda Y; Yusa K
Virology; 2008 Jan; 370(1):142-50. PubMed ID: 17900650
[TBL] [Abstract][Full Text] [Related]
15. Rapid selection for an N-linked oligosaccharide by monoclonal antibodies directed against the V3 loop of human immunodeficiency virus type 1.
Schønning K; Jansson B; Olofsson S; Hansen JE
J Gen Virol; 1996 Apr; 77 ( Pt 4)():753-8. PubMed ID: 8627264
[TBL] [Abstract][Full Text] [Related]
16. Use of synthetic peptides for the production of site (amino acid) specific polyclonal and monoclonal antibodies.
Claassen E; Zegers ND; Laman JD; Boersma WJ
Year Immunol; 1993; 7():150-61. PubMed ID: 7690507
[No Abstract] [Full Text] [Related]
17. HIV vaccine design and the neutralizing antibody problem.
Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT
Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706
[No Abstract] [Full Text] [Related]
18. Neutralizing antibody response during human immunodeficiency virus type 1 infection: type and group specificity and viral escape.
Arendrup M; Sönnerborg A; Svennerholm B; Akerblom L; Nielsen C; Clausen H; Olofsson S; Nielsen JO; Hansen JE
J Gen Virol; 1993 May; 74 ( Pt 5)():855-63. PubMed ID: 7684062
[TBL] [Abstract][Full Text] [Related]
19. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.
Shibata J; Yoshimura K; Honda A; Koito A; Murakami T; Matsushita S
J Virol; 2007 Apr; 81(8):3757-68. PubMed ID: 17251298
[TBL] [Abstract][Full Text] [Related]
20. Dual specificity of a monoclonal anti-idiotypic antibody for HIV-1 neutralizing monoclonals 110.3 and 110.4 as well as the V3 loop of gp120.
Connelly RJ; Kahn M; Blake J; Haffar OK; Thomas EK
Virology; 1994 Dec; 205(2):554-7. PubMed ID: 7526543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
